References: Sodium-glucose co-transporter 2 inhibitors for HFrEF

  • McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019;381(21):1995-2008. https://www.ncbi.nlm.nih.gov/pubmed/31535829
  • Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020;383(15):1413-24. https://www.ncbi.nlm.nih.gov/pubmed/32865377
  • Rasalam R, Atherton JJ, Deed G, Molloy-Bland M, Cohen N, Sindone A. Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Fail 2021;8(5):4093-118. https://www.ncbi.nlm.nih.gov/pubmed/34219407